Skip to main content
. 2020 Sep 22;21(18):6968. doi: 10.3390/ijms21186968

Figure 2.

Figure 2

Association of CD8 T cells’ score and subtypes with neoadjuvant treatment chemotherapy (NAC) response and survival within each subtype. (A) Boxplots of the CD8 score by immunohistochemistry (IHC) determined subtype and PAM50 classification in the TCGA and METABRIC cohorts. One-way ANOVA was used to calculate p value. (B) Bar plots of the pathological complete response (pCR) rate between low- and high CD8 score in TNBC and estrogen receptor (ER)-positive/HER2-negative in the GSE20194 (n = 197), GSE25066 (n = 467), and GSE32646 (n = 115) breast cancer cohorts that underwent neoadjuvant chemotherapy (NAC). Fisher’s test was used to calculate p value. (C) Disease-Specific Survival (DSS) of CD8 score low (blue line) and high (red line) within each subtype; TNBC, ER-positive/HER2-negative, and HER2-positive, in the TCGA and METABRIC cohorts. Kaplan–Meier survival curves with log-rank test were used for the analysis.